Here is the mechanistic deep dive
How HSP27 actually works, and why HSP90 behaves differently.
HSP27 is the canonical first protein transcribed when the heat-shock response fires. The master transcription factor HSF1 sits inactive at rest, complexed with HSP90. Heat unfolds proteins, HSP90 leaves HSF1 to chaperone the misfolded clients, and the released HSF1 drives HSP27 expression. This is exactly why HSP90 in my data does not look like HSP27. HSP90 is the regulator, not the target. It gets consumed and redistributed during heat stress. HSP27 is a canonical induced output in response to heat stress (Arrigo 2017).
Once expressed, HSP27 is phosphorylated at three serines (Ser15, Ser78, Ser82) by p38 MAPK-MAPKAPK-2 kinases (Landry 1992; Kostenko & Moens 2009). Phosphorylation triggers oligomeric rearrangement and packaging into exosomes, which release HSP27 into the bloodstream (Stope 2017; Batulan 2016). Serum HSP27, which is what I measured, is the downstream readout of that entire cascade.
Once in circulation, HSP27 produces three downstream effects, each with mechanistic evidence supporting it.
Anti-inflammatory hormesis. Extracellular HSP27 binds TLR-4 on monocytes and macrophages, activates p38 MAPK, and drives a potent IL-10 release with only modest TNF-α induction (De 2000; Salari 2013). My IL-6 ( 360%, 29%) and TNF-α ( 18%, 70%) elevations are mostly direct heat-stress responses, since IL-6 and TNF-α are themselves heat-induced cytokines independent of HSP27.
The HSP27-attributable signal is the controlled inflammation brake: IL-10 climbed 137% and 184%, simultaneously with the IL-6/TNF-α pulse.
Prevention of plaque formation. Two parallel mechanisms. First, extracellular HSP27 directly competes with oxidized LDL for binding to scavenger receptor-A, blocking macrophage uptake of the oxidized cholesterol that initiates foam cell formation, an early step in plaque formation (Rayner 2008). Second, HSP27 activates NF-κB in macrophages, driving GM-CSF release, which maintains ABCA1 and ABCG1 expression and enables reverse cholesterol transport out of arterial wall macrophages (Salari 2013; Raizman 2017). In ApoE-/- mouse models, chronic HSP27 elevation reduces atherosclerotic lesion area by 21 to 35% (Rayner 2009; Cuerrier 2013). In human cohorts, low circulating HSP27 associates with increased cardiovascular events (Seibert 2013).
Vascular remodeling. Extracellular HSP27 also induces VEGF-A release from monocytes, the upstream signal of the angiogenic program that years of consistent heat exposure can produce structurally (HSP Immune Network review 2021). VEGF-A in my acute panel rose modestly ( 6.4% and 9.1%), consistent with this being the a slow process of structural adaptation to heat, not an acute high-magnitude pulse. The match to my own multi-year VEGF rise (up to 20-fold across HBOT sauna protocols) is what gives the acute small increase a potential meaning.